Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (471-480 of 557) with videos related to

Pageof 56
Sort By:
JACC. Heart Failure|September 16, 2019
CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH TrialJonathan G Howlett, Amanda Stebbins, Mark C Petrie, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 1998
Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertensionJ A Staessen, L Thijs, R H Fagard, et al.
European Journal of Heart Failure|August 8, 2024
Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of CardiologyKaren Sliwa, Amina Rakisheva, Charle Viljoen, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
International Journal of Cardiology|November 18, 2023
Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: A study of the ESC EORP PPCM registryKaren Sliwa, Peter van der Meer, Charle Viljoen, et al.
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
European Journal of Heart Failure|June 28, 2019
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathyJohann Bauersachs, Tobias König, Peter van der Meer, et al.
Pageof 56

Showing results (471-480 of 557) with videos related to

Sort By:
Pageof 56
JACC. Heart Failure|September 16, 2019
CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH TrialJonathan G Howlett, Amanda Stebbins, Mark C Petrie, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 1998
Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertensionJ A Staessen, L Thijs, R H Fagard, et al.
European Journal of Heart Failure|August 8, 2024
Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of CardiologyKaren Sliwa, Amina Rakisheva, Charle Viljoen, et al.
Circulation. Heart Failure|June 23, 2023
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, Karola S Jering, Pardeep S Jhund, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
International Journal of Cardiology|November 18, 2023
Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: A study of the ESC EORP PPCM registryKaren Sliwa, Peter van der Meer, Charle Viljoen, et al.
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
European Journal of Heart Failure|June 28, 2019
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathyJohann Bauersachs, Tobias König, Peter van der Meer, et al.
Pageof 56